4TZ.F ORIC PHARMAC.INC.DL-0001

Healthcare Biotechnology Frankfurt Exchange
7.90 EUR
Close of Nov 11, 2026
6.10 12.33
Market cap
EUR 818M
P/E
-
P/B
2.43x
ROE
-40.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4TZ.F undervalued?

Graham number

The Graham number of ORIC PHARMAC.INC.DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ORIC PHARMAC.INC.DL-0001 fundamental analysis

No fundamental analysis for ORIC PHARMAC.INC.DL-0001 yet.

ORIC PHARMAC.INC.DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ORIC PHARMAC.INC.DL-0001

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth fact…

Full company profile